|
|
2 Park Plaza, Suite 450
Irvine, CA 92614 USA
phone:949-733-1101
fax:949-266-8426
|
|
| Symbol |
DMSI |
| Exchange |
.PK |
| Founded |
2004 |
| Employees |
1 |
|
|
| www.dermisonics.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Improve the quality of life of patients who are required to follow a drug regimen |
|
| Management |
| Bruce Haglund, Chief Executive Officer, Chairman of the Board; Bruce K. Redding, Member of the Board of Directors; Grant Atkins |
| |
|
|
|
|
|
|
|
| Keywords |
| non-invasive, drug delivery, insulin, large molecule, transdermal, insulin, DrugDelivery |
|
|
|
| Description |
|
Dermisonics develops and markets needle-free ultrasonic transdermal and subdermal patch technologies for non-invasive delivery of drugs with large molecular structures into the bloodstream. |
|
| Products / Services |
The company's products include the U-Strip for drug delivery, the U-Wand for skin care and the A-Wand for antiseptic wound care
The U-Wand is an ultrasonic cosmetic applicator device that is used to apply skin care compounds topically to the surface of the skin.
The A-Wand is a hand held, portable, ultrasonic wand device for applying antiseptic solutions to cuts, abrasions, and wounds with a replaceable Patch-Cap, which holds up to 40 ml of antiseptic cream.
|
|
| Technology / Differentiation |
| The company's U-Strip system is based on a radical integration of microelectronics and ultrasonic science with a product-carrying patch. It uses alternating ultrasonic waveforms to enlarge the diameter of pores, enabling large molecule drugs, such as insulin, to permeate into the skin through the sweat pores and then into the bloodstream. |
|
| Market / Customers |
Dermisonics serves three primary markets:
The $17.6 billion skin care market and the anti-aging needs of the 270 million graying baby boomers in the U.S and Europe alone.
The $19 billion drug delivery market treating the 55 million diabetics worldwide forced to use painful needles to survive this debilitating disease.
The $1.2 billion antiseptic market for consumers at home and to combat the critical problem of infections for soldiers wounded on the battlefield.
|
|
| Competitors / Substitutes / Alternatives |
Altea Therapeutics Corporation and BioDelivery Sciences International Inc.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members